Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 4, 1999, Pages 503-506

  Hoffman, J S ^a   Katz, L M ^a   Cave, D R ^a  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; CLARITHROMYCIN; METRONIDAZOLE; RANITIDINE BISMUTH CITRATE; UREA;

ADULT; ARTICLE; BACTERIAL INFECTION; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ENDOSCOPY; ETHNIC GROUP; FEMALE; HELICOBACTER PYLORI; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEROLOGY; TASTE DISORDER; THRUSH; VAGINA CANDIDIASIS;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; RANITIDINE;

EID: 0032923227     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00498.x     Document Type: Article

References (16)

1. NIH consensus panel on Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
2. Hunt RH, Mohammed AH. The current role of Helicobacter pylori eradication in clinical practice. Scand J Gastroenterol 1995; 30(Suppl. 208): 47-52.
3. Fennerty MB. What are the treatment goals for Helicobacter pylori infection. Gastroenterology 1997; 113: S120-5.
4. Thijis JC, Van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 934-8.
5. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
6. McColm AA, McLauren A, Klinkert G, et al. R anitidine bismuth citrate: A novel anti-ulcer agent with different physicochemical characteristics and improved biological activity to a bismuth citrate ranitidine admixture. Aliment Pharmacol Ther 1996; 10: 241-50.
7. Hopkins RJ. Current FDA-approved treatment for H. pylori and the FDA approval process. Gastroenterology 1997; 113: S126-30.
8. DeBoer WA, Tytgat GNJ. 90% cure: Which anti-Helicobacter therapy can achieve this goal? Am J Gastroenterol 1995; 90: 1381-2.
9. Grayham DY. A reliable cure for H. pylori infection? Gut 1995; 37: 154-6.
10. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus report. Gut 1997; 41: 8-13.
11. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobials. The MACH 1 Study. Helicobacter 1996; 1: 138-44.
12. de Boer WA, Haeck P, Otten MH, Mulder C. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate: A randomized comparison between two 7 day triple therapies and a 14 day dual therapy. Am J Gastroenterol 1998; 93: 1101-7.
13. van der Wouden EJ, Thijs JC, Van Zwet AA, et al. One week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: A randomized, clinical trial. Am J Gastroenterol 1998; 93: 1228-31.
14. Laine L, Estrada R, Trujilio E, et al. Randomized comparison of ranitidine bismuth citrate based triple therapies for H. pylori. Am J Gastroenterol 1998; 92: 2213-15.
15. Dore MP, Are B, Carta M, et al. Antibiotic resistant H. pylori are extremely common in Sardinia. Gastroenterology 1998; 114: A108(Abstract).
16. Morton D, Ahmed R, Ally R, et al. Helicobacter pylori antimicrobial susceptability: A tale of two cities. Gastroenterology 1998; 114: A234(Abstract).